The safety of EVRA was evaluated in 3330 sexually active women who participated in three Phase III clinical trials, which were designed to evaluate contraceptive efficacy. These subjects received six or 13 cycles of contraception (EVRA or oral contraceptive comparator), took at least one dose of study medication and provided safety data.
The most common adverse reactions reported during clinical trials were breast symptoms, headache, application site disorder and nausea. The most common events leading to discontinuation were application site reaction, breast symptoms (including breast discomfort, breast engorgement and female breast pain), nausea, headache and emotional lability.
Adverse reactions reported by ≥ 1% of EVRA-treated subjects in these trials are shown in Table 3. (See Table 3.)
Click on icon to see table/diagram/image
Additional adverse reactions that occurred in < 1% of EVRA-treated subjects in the previously mentioned clinical trial dataset are listed in Table 4. (See Table 4.)
Click on icon to see table/diagram/image
Postmarketing Data: Additional adverse reactions first identified during postmarketing experience with EVRA are included in Table 5. In each table, the frequencies are provided according to the following convention: Very common ≥ 1/10; Common ≥ 1/100 and < 1/10; Uncommon ≥ 1/1000 and < 1/100; Rare ≥ 1/10000 and < 1/1,000; Very rare < 1/10000, including isolated reports; Not known: Cannot be estimated from the available data.
In Table 5, adverse reactions are presented by frequency category based on spontaneous reporting rates. (See Table 5.)
Click on icon to see table/diagram/image
View ADR Monitoring Form